X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
MYLAN
Dec-14
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2853,802-   
Low Rs6342,679-   
Sales per share (Unadj.) Rs189.61,301.5-  
Earnings per share (Unadj.) Rs-0.2156.8-  
Cash flow per share (Unadj.) Rs3.8252.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6647.0-  
Shares outstanding (eoy) m25.00378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 203.3%   
Avg P/E ratio x-4,712.720.7 -22,801.8%  
P/CF ratio (eoy) x249.612.8 1,943.8%  
Price / Book Value ratio x14.05.0 279.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9881,226,120 2.0%   
No. of employees `0001.625.0 6.2%   
Total wages/salary Rs m1,6050-   
Avg. sales/employee Rs Th3,040.219,698.4 15.4%   
Avg. wages/employee Rs Th1,029.20-   
Avg. net profit/employee Rs Th-3.32,373.0 -0.1%   
INCOME DATA
Net Sales Rs m4,740492,459 1.0%  
Other income Rs m92-2,871 -3.2%   
Total revenues Rs m4,832489,588 1.0%   
Gross profit Rs m-130122,477 -0.1%  
Depreciation Rs m10136,169 0.3%   
Interest Rs m021,242 0.0%   
Profit before tax Rs m-13962,195 -0.2%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m52,615 0.2%   
Profit after tax Rs m-559,325 -0.0%  
Gross profit margin %-2.724.9 -11.0%  
Effective tax rate %-3.74.2 -87.1%   
Net profit margin %-0.112.0 -0.9%  
BALANCE SHEET DATA
Current assets Rs m2,726432,936 0.6%   
Current liabilities Rs m2,435338,470 0.7%   
Net working cap to sales %6.119.2 32.1%  
Current ratio x1.11.3 87.5%  
Inventory Days Days7478 94.5%  
Debtors Days Days41107 38.0%  
Net fixed assets Rs m1,035113,929 0.9%   
Share capital Rs m5017,415 0.3%   
"Free" reserves Rs m9420-   
Net worth Rs m1,716244,801 0.7%   
Long term debt Rs m0365,708 0.0%   
Total assets Rs m4,156986,034 0.4%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.10.5 228.3%   
Return on assets %-0.18.2 -1.5%  
Return on equity %-0.324.2 -1.2%  
Return on capital %013.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-864,734 -0.0%  
From Investments Rs m-146-51,051 0.3%  
From Financial Activity Rs m862-17,057 -5.1%  
Net Cashflow Rs m709-3,374 -21.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.79 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: PANACEA BIOTECH  IPCA LABS  ELDER PHARMA  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 23, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - J.B.CHEMICALS COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS